BioSpace News Archive

SQZ Biotechnologies today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05 - 5:30 p.m. ET.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent operational highlights.

Neurelis, Inc., today announced findings from a novel, exploratory analysis of VALTOCO® (diazepam nasal spray).

Agile Therapeutics, Inc., a women’s healthcare company, publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla® transdermal system.

Baudax Bio, Inc., a pharmaceutical company focused on innovative products for acute care settings, announced that it has adjourned its 2022 Annual Meeting of Shareholders, without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum.

Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick.

The U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.

Bausch + Lomb Corporation (“Bausch + Lomb”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced the pricing of its initial public offering (“IPO”) of 35,000,000 common shares at a public offering price of $18.00 per share.

Scilex Holding Company (“Scilex”), announced pivotal Phase 3 SEMDEXATM data presentation at the American Society of Interventional Pain 2022 annual meeting.

Antengene Corporation Limited announced that the Company will be participating virtually in three upcoming investor conferences.